Tacrolimus ointment: A review of its use in atopic dermatitis and its clinical potential in other inflammatory skin conditions

Drugs

Volumn 65, Issue 6, 2005, Pages 827-858

  Simpson, Dene ^a   Noble, Stuart ^a  

^a ADIS INTERNATIONAL LIMITED   (New Zealand)

Author keywords

[No Author keywords available]

Indexed keywords

BETAMETHASONE VALERATE; CALCIPOTRIOL; CLOBETASOL; CORTICOSTEROID; HYDROCORTISONE ACETATE; HYDROCORTISONE BUTYRATE; IMMUNOMODULATING AGENT; MOMETASONE FUROATE; PETROLATUM; PIMECROLIMUS; TACROLIMUS;

ACNE; ALCOHOL INTOLERANCE; AREA UNDER THE CURVE; ATOPIC DERMATITIS; CONTACT DERMATITIS; COST EFFECTIVENESS ANALYSIS; DOSE RESPONSE; DRUG ABSORPTION; DRUG EFFICACY; DRUG MECHANISM; DRUG TOLERABILITY; ERYTHEMA; FACE; FLU LIKE SYNDROME; FLUSHING; FOLLICULITIS; GENE EXPRESSION; HEADACHE; HEAT SENSATION; HUMAN; HYPERESTHESIA; LICHEN PLANUS; LONG TERM CARE; PATHOPHYSIOLOGY; PRURITUS; PSORIASIS; RASH; REVIEW; ROSACEA; SEBORRHEIC DERMATITIS; SIDE EFFECT; SKIN ATROPHY; SKIN BURNING SENSATION; SKIN INFECTION; SKIN INFLAMMATION; SKIN IRRITATION; SKIN TINGLING; SKINFOLD; T LYMPHOCYTE; VITILIGO;

ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; DERMATITIS, ATOPIC; HUMANS; IMMUNOSUPPRESSIVE AGENTS; OINTMENTS; SKIN DISEASES; TACROLIMUS;

EID: 17944364504     PISSN: 00126667     EISSN: None     Source Type: Journal    
DOI: 10.2165/00003495-200565060-00011     Document Type: Review

References (200)

1. Boguniewicz M. Combination therapy and new directions for managing atopic dermatitis. Allergy Asthma Proc 2002 Jul; 23 (4): 243-6
2. Lamb SR, Rademaker M. Pharmacoeconomics of drug therapy for atopic dermatitis. Expert Opin Pharmacother 2002 Mar; 3 (3): 249-55
3. Bernard LA, Eichenfield LF. Topical immunomodulators for atopic dermatitis. Curr Opin Pediatr 2002 Aug; 14 (4): 414-8
4. Russell JJ. Topical tacrolimus: a new therapy for atopic dermatitis. Am Fam Physician 2002 Nov 15; 66 (10): 1899-902
5. Alomar A, Berth-Jones J, Bos JD, et al. The role of topical calcineurin inhibitors in atopic dermatitis. Br J Dermatol 2004 Dec; 151 Suppl. 70: 3-27
6. Williams H. New treatments for atopic dermatitis. BMJ 2002 Jun 29; 324 (7353): 1533-4
7. Allen BR. Tacrolimus ointment: its place in the therapy of atopic dermatitis. J Allergy Clin Immunol 2002 Mar; 109 (3): 401-3
8. Boucher M. Tacrolimus ointment for the treatment of atopic dermatitis. Issues Emerg Health Technol 2001 Jul; (19): 1-4
9. Leung DYM. Immunopathogenesis of atopic dermatitis. Immunol Allergy Clin North Am 2002; 22 (1): 73-90
10. Rustin M. Tacrolimus ointment for the management of atopic dermatitis. Hosp Med 2003 Apr; 64 (4): 214-7
11. Marsland AM, Griffiths CE. The macrolide immunosuppressants in dermatology: mechanisms of action. Eur J Dermatol 2002 Nov-2002 31; 12 (6): 618-22
12. Lawrence I. Tacrolimus (FK506): experience in dermatology. Dermatol Ther 1998; 5: 74-84
13. Reynolds NJ, Al-Daraji WI. Calcineurin inhibitors and sirolimus: mechanisms of action and applications in dermatology. Clin Exp Dermatol 2002 Oct; 27 (7): 555-61
14. Cheer SM, Plosker GL. Tacrolimus ointment, a review of its therapeutic potential as a topical therapy in atopic dermatitis. Am J Clin Dermatol 2001; 2 (6): 389-406
15. Leung DYM, Bieber T. Atopic dermatitis. Lancet 2003; 361: 151-60
16. Wollenberg A, Kraft S, Oppel T, et al. Atopic dermatitis: pathogenetic mechanisms. Clin Exp Dermatol 2000; 25: 530-4
17. Meagher LJ, Wines NY, Cooper AJ. Atopic dermatitis: review of immunopathogenesis and advances in immunosuppressive therapy. Australas J Dermatol 2002 Nov; 43 (4): 247-54
18. Leung DY, Hanifin JM, Charlesworth EN, et al. Disease management of atopic dermatitis: a practice parameter. Joint Task Force on Practice Parameters, representing the American Academy of Allergy, Asthma and Immunology, the American College of Allergy, Asthma and Immunology, and the Joint Council of Allergy, Asthma and Immunology. Work Group on Atopic Dermatitis. Ann Allergy Asthma Immunol 1997 Sep; 79 (3): 197-211
19. Assmann T, Homey B, Ruzicka T. Topical tacrolimus for the treatment of inflammatory skin diseases. Expert Opin Pharmacother 2001 Jul; 2 (7): 1167-75
20. Gupta AK, Adamiak A, Chow M. Tacrolimus: a review of its use for the management of dermatoses. J Eur Acad Dermatol Venereol 2002 Mar; 16 (2): 100-14
21. Thomson AW, Bonham CA, Zeevi A. Mode of action of tacrolimus (FK506): molecular and cellular mechanisms. Ther Drug Monit 1995; 17: 584-91
22. Grewe M, Bruijnzeel-Koomen CA, Schopf E, et al. A role for Th1 and Th2 cells in the immunopathogenesis of atopic dermatitis. Immunol Today 1998; 19: 359-61
23. Pustisek N, Lipozencic J, Ljubojevic S. Tacrolimus ointment: a new therapy for atopic dermatitis: review of the literature. Acta Dermatovenerol Croat 2002 Mar; 10 (1): 25-32
24. Bornhovd E, Burgdorf WHC, Wollenberg A. Macrolactam immunomodulators for topical treatment of inflammatory skin diseases. J Am Acad Dermatol 2001 Nov; 45 (5): 736-43
25. Meingassner JG, Stutz A. Anti-inflammatory effects of macrophilin-interacting drugs in animal models of irritant and allergic contact dermatitis. Int Arch Allergy Immunol 1992; 99 (2-4): 486-9
26. Meingassner JG, Stutz A. Immunosuppressive macrolides of the type FK 506: a novel class of topical agents for treatment of skin diseases? J Invest Dermatol 1992; 98: 851-5
27. Lauerma AI, Stein BD, Homey B, et al. Topical FK506: suppression of allergic and irritant contact dermatitis in the guinea pig. Arch Dermatol Res 1994; 286: 337-40
28. Lauerma AI, Maibach HI, Granlund H, et al. Inhibition of contact allergy reactions by topical FK506 [letter]. Lancet 1992; 340: 556
29. Duncan JI. Differential inhibition of cutaneous T-cell-mediated reactions and epidermal cell proliferation by cyclosporin A, FK-506, and rapamycin. J Invest Dermatol 1994; 102: 84-8
30. Eberlein-Konig B, Michel G, Ruzicka T, et al. Modulation of histamine release in vitro by FK506 and interleukin-3 is determined by sequence of incubation. Arch Dermatol Res 1997; 289: 606-8
31. Eberlein-Konig B, Ruzicka T, Michel G, et al. Inhibition of in vitro histamine release (HR) from human basophils by the immunosuppressive drug FK506. J Invest Dermatol 1993; 100: 446
32. de Paulis A, Cirillo R, Ciccarelli A, et al. Antiinflammatory effect of FK 506 on human basophils. Transplant Proc 1991; 23: 2905-6
33. de Paulis A, Cirillo R, Ciccarelli A, et al. FK-506, a potent novel inhibitor of the release of proinflammatory mediators from human FceRI+ cells. J Immunol 1991; 146: 2374-85
34. de Paulis A, Stellato C, Cirillo R, et al. Anti-inflammatory effect of FK-506 on human skin mast cells. J Invest Dermatol 1992; 99: 723-8
35. Fujii Y, Sakuma S, Senoh H, et al. Topical tacrolimus is more efficacious than pimecrolimus in inhibiting acute contact dermatitis in a rat model. J Invest Dermatol 2002 Sep; 119: 727
36. Sengoku T, Morita K, Sato S. Effects of tacrolimus ointment on type I (immediate and late) and IV (delayed) cutaneous allergic reactions in mice. Folia Pharmacol Jpn 1998; 112: 221-32
37. Hiroi J, Sengoku T, Morita K, et al. Effect of tacrolimus hydrate (FK506) ointment on spontaneous dermatitis in NC/Nga mice. Jpn J Pharmacol 1998 Feb; 76: 175-83
38. Hultsch T, Brand P, Lohmann S, et al. Direct evidence that FK506 inhibition of FCERI-mediated exocytosis from RBL mast cells involves calcineurin. Arch Dermatol Res 1998; 290: 258-63
39. Panhans-Grob A, Novak N, Kraft S, et al. Human epidermal Langerhans' cells are targets for the immunosuppressive macrolide tacrolimus (FK506). J Allergy Clin Immunol 2001; 107: 345-52
40. Nghiem P, Pearson G, Langley RG. Tacrolimus and pimecrolimus: from clever prokaryotes to inhibiting calcineurin and treating atopic dermatitis. J Am Acad Dermatol 2002 Feb; 46 (2): 228-41
41. Plosker GL, Foster RH. Tacrolimus: a further update of its pharmacology and therapeutic use in the management of organ transplantation. Drugs 2000; 59 (2): 323-89
42. Spencer CM, Goa KL, Gillis JC. Tacrolimus: an update of its pharmacology and clinical efficacy in the management of organ transplantation. Drugs 1997; 54 (6): 925-75
43. Mori A, Suko M, Nishizaki Y, et al. Regulation of interleukin-5 production by peripheral blood mononuclear cells from atopic patients with FK506, cyclosporin A and glucocorticoid. Int Arch Allergy Immunol 1994; 104 (1): 32-5
44. Khanna A, Cairns V, Hosenpud JD. Tacrolimus induces increased expression of transforming growth factor-α1 in mammalian lymphoid as well as nonlymphoid cells. Transplantation 1999; 67: 614-9
45. Rico MJ, Lawrence I. Tacrolimus ointment for the treatment of atopic dermatitis: clinical and pharmacologic effects. Allergy Asthma Proc 2002 May-2002 30; 23 (3): 191-7
46. Wollenberg A, Sharma S, van Bubnoff D, et al. Topical tacrolimus (FK506) leads to profound phenotypical and functional alterations of epidermal antigen-presenting dendritic cells in atopic dermatitis. J Allergy Clin Immumol 2001; 107 (3): 519-25
47. Schuller E, Oppel T, Bornhoud E, et al. Tacrolimus ointment causes inflammatory dendritic epidermal cell depletion but no Langerhans cell apoptosis in patients with atopic dermatitis. J Allergy Clin Immunol 2004; 114: 137-43
48. Marone G. Tacrolimus ointment for atopic dermatitis [letter]. N Engl J Med 1998; 339: 1788
49. Sakuma S, Higashi Y, Sato N, et al. Tacrolimus suppressed the production of cytokines involved in atopic dermatitis by direct stimulation of human PBMC system. (Comparison with steroids). Int Immunopharmacol 2001; 1: 1219-26
50. Sengoku T, Kishi S, Sakuma S, et al. FK506 inhibition of histamine release and cytokine production by mast cells and basophils. Int J Immunopharmacol 2000; 22 (3): 189-201
51. Sperr WR, Agis H, Czerwenka K, et al. Effects of cyclosporin A and FK-506 on stem cell factor-induced histamine secretion and growth of human mast cells. J Allergy Clin Immunol 1996; 98: 389-99
52. Patella V, Giuliano A, Bouvet J-P, et al. Endogenous superallergen protein Fv induces IL-4 secretion from human FceR1+ cells through interaction with the VH3 region of IgE1. J Immunol 1998; 161: 5647-55
53. Bornhovd EC, Burgdorf WHC, Wollenberg A. Immunomodulatory macrolactams for topical treatment of inflammatory skin diseases. Curr Opin Investig Drugs 2002 May; 3 (5): 708-12
54. Wollenberg A, Wen S, Bieber T. Phenotyping of epidermal dendritic cells: clinical applications of a flow cytometric micromethod. Cytometry 1999; 37: 147-55
55. Wollenberg A, Regele D, Sharma S, et al. Topical tacrolimus treatment leads to profound alterations of the antigen presenting cells in lesional atopic dermatitis skin. J Invest Dermatol 1996 Sep; 107: 468
56. Katoh N, Hirano S, Yasuna H, et al. Effects of tacrolimus ointment on facial eruption, itch and scratching in patients with atopic dermatitis. J Dermatol 2004; 31 (3): 194-9
57. Toyoda M. Antipruritic mechanism of tacrolimus ointment for atopic dermatitis: consideration of dermatoneuronal factors. Clin Dermatol 2003; 57 (5): 45-50
58. Remitz A, Kyllonen H, Granlund H, et al. Tacrolimus ointment reduces staphylococcal colonization of atopic dermatitis lesions. J Allergy Clin Immunol 2001; 107 (1): 196-7
59. Pournaras CC, Lubbe J, Saurat J-H. Staphylococcal colonization in atopic dermatitis treatment with topical tacrolimus (FK506). J Invest Dermatol 2001; 116 (3): 480-1
60. Reitamo S, Wollenberg A, Schopf E, et al. Safety and efficacy of 1 year of tacrolimus ointment monotherapy in adults with atopic dermatitis. Arch Dermatol 2000; 136: 999-1006
61. Ling MR. Topical tacrolimus and pimecrolimus: future directions. Semin Cutan Med Surg 2001 Dec; 20 (4): 268-74
62. Nakagawa H, Etoh T, Yokota Y, et al. Tacrolimus has antifungal activities against Malassezia furfur isolated from healthy adults and patients with atopic dermatitis. Clin Drug Invest 1996 Nov; 12: 244-50
63. Wollenberg A, for the European Tacrolimus Multicenter Atopic Dermatitis Study Group. Long-term efficacy and safety of tacrolimus ointment in adult patients with atopic dermatitis [abstract no. 013]. 58th Annual Meeting of the American Academy of Dermatology; 2000 Mar 10-15; San Francisco
64. Marcil I, Stern RS. Squamous-cell cancer of the skin in patients given PUVA and ciclosporin: nested cohort crossover study. Lancet 2001; 358: 1042-5
65. National Institute for Clinical Excellence. Atopic eczema in primary care. Merec Bull 2003 Jul; 14(1): 1-4
66. Bekersky I, Lilja H, Lawrence I. Tacrolimus pharmacology and nonclinical studies: from FK506 to Protopic. Semin Cutan Med Surg 2001 Dec; 20 (4): 226-32
67. Food and Drug Administration Center for Drug Evaluation and Research. Pharmacologist's view of new drug application 50777 [Protopic (Tacrolimus ointment) approval online; online]. Available from URL: http://www.fda.gov/cder [Accessed 2005 Feb 5]
68. Bekersky I, Ohara K, Dressler D, et al. An evaluation of the phototoxicily of tacrolimus (FK506) ointment in hairless mice. Int J Toxicology 1998; 17: 541-50
69. Jiang H, Yamamoto S, Nishikawa K, et al. Anti-tumour promoting action of FK506, a potent immunosuppressive agent. Carcinogenesis 1993; 14 (1): 67-71
70. Niwa Y, Terashima T, Sumi H. Topical application of the immunosuppressant tacrolimus accelerates carcinogenesis in mouse skin. Br J Dermatol 2003 Nov; 149 (5): 960-7
71. Naylor MF, Elmets C, Satoi Y, et al. Treatment with topical tacrolimus is not associated with an increase in non-melanoma skin cancers [abstract no. P18]. 60th Annual Meeting of the American Academy of Dermatology; 2002 Feb 22-27; New Orleans
72. Robinson N, Singri P, Gordon KB. Safety of the new macrolide immunomodulators. Semin Cutan Med Surg 2001 Dec; 20 (4): 242-9
73. Rico MJ, Naylor M, Elmets CA, et al. Treatment with tacrolimus ointment is not associated with an increase in non-melanoma skin cancer [abstract no. PPI-30]. 1st EADV International Spring Symposium; 2003 Feb 27-Mar 1; St Julian's, Malta
74. Brazzini B, Pimpinelli N. New and established topical corticosteroids in dermatology. Am J Clin Dermatol 2002; 3 (1): 47-58
75. Spencer CM, Wiseman LR. Topical fluticasone propionate: a review of its pharmacological properties and therapeutic use in the treatment of dermatological disorders. Biodrugs 1997 Apr; 7: 318-34
76. Worm M. Novel therapies for atopic eczema. Curr Opin Investig Drugs 2002 Nov; 3 (11): 1596-603
77. Kikuchi K, Tagami H. Comparison of the effects of daily applications between topical corticosteroid and tacrolimus ointments on normal skin: evaluation with noninvasive methods. Dermatology 2002; 205 (4): 378-82
78. Hisatomi A, Mitamura T, Kimura M, et al. Comparison of FK506 (tacrolimus) and glucocorticoid ointment on dermal atrophogenicity in rats. J Toxicol Pathol 1997; 10 (2): 97-102
79. Reitamo S, Rissanen J, Remitz A, et al. Tacrolimus ointment does not affect collagen synthesis: results of a single-center randomized trial. J Invest Dermatol 1998; 111: 396-8
80. Kyllonen H, Remitz A, Mandelin JM. Effects of 1-year intermittent treatment with topical tacrolimus monotherapy on skin collagen synthesis in patients with atopic dermatitis. Br J Dermatol 2004 Jun; 150 (6): 1174-81
81. Alaiti S, Kang S, Fiedler VC, et al. Tacrolimus (FK506) ointment for atopic dermatitis: a phase 1 study in adults and children. J Am Acad Dermatol 1998; 38: 69-76
82. Hanifin JM, Ling MR, Langley R, et al. Tacrolimus ointment for the treatment of atopic dermatitis in adult patients. Part I: efficacy. J Am Acad Dermatol 2001 Jan; 44 (1): S28-38
83. Soter N, Ling M, Fleischer A, et al. Topically applied tacrolimus ointment vs vehicle ointment in adult patients with atopic dermatitis [poster no. 109]. 58th Annual Meeting of the American Academy of Dermatology; 2000 Mar 10-15; San Francisco
84. Hanifin J, Sober A, Lawrence I, et al. Comparison of topically applied tacrolimus ointment vs. vehicle ointment in adult patients with atopic dermatitis [abstract no. 16]. 58th Annual Meeting of the American Academy of Dermatology: 2000 Mar 10-15; San Francisco
85. Paller A, Eichenfield LF, Leung DYM. et al. A 12-week study of tacrolimus ointment for the treatment of atopic dermatitis in pediatric patients. J Am Acad Dermatol 2001: 44 (1): S47-57
86. Boguniewicz M, Fiedler VC, Raimer S. et al. A randomized, vehicle-controlled trial of tacrolimus ointment for treatment of atopic dermatitis in children. J Allergy Clin Immunol 1998; 102 (4 Pt 1): 637-44
87. Fujisawa. Protopic® (tacrolimus) ointment 0.03% and 0.1% prescribing information. Deerfield (IL): Fujisawa. 2000
88. Undre N, Rubins A, Gutmane R, et al. Pharmacokinetics of tacrolimus ointment in adult patients with moderate to severe atopic dermatitis. Ann Dermatol Venereol 2002 Jul; 129 Suppl.: 425
89. Undre N, Green A, Harper J, et al. Tacrolimus pharmacokinetics in paediatric patients with moderate to severe atopic dermatitis after single and repeated application. Ann Dermatol Venereol 2002 Jul; 129 Suppl.: 424
90. Kapp A, Allen BR, Reitamo S. Atopic dermatitis management with tacrolimus ointment (Protopic®). J Dermatol Treat 2003; 14 Suppl. 1: 5-16
91. Kameda G, Kramm C, Niehues T, et al. Unexpected high serum levels of tacrolimus after a single topical application in an infant [letter]. J Pediatr 2003 Aug; 143 (2): 280
92. Teshima D, Ikesue H, Itoh Y, et al. Increased topical tacrolimus absorption on generalized leukemic erythroderma. Ann Pharmacol 2003 Oct; 37: 1444-7
93. Ruzicka T, Bieber T, Schopf E, et al. A short-term trial of tacrolimus ointment for atopic dermatitis. N Engl J Med 1997 Sep 18; 337: 816-21
94. Reitamo S, Van Leent EJ, Ho V, et al. Efficacy and safety of tacrolimus ointment compared with that of hydrocortisone acetate ointment in children with atopic dermatitis. J Allergy Clin Immunol 2002 Mar; 109 (3): 539-46
95. Reitamo S, Rustin M, Ruzicka T, et al. Efficacy and safety of tacrolimus ointment compared with that of hydrocortisone butyrate ointment in adult patients with atopic dermatitis. J Allergy Clin Immunol 2002 Mar; 109 (3): 547-55
96. Ohtsuki M. Tacrolimus ointment is effective and safe in Japanese atopic dermatitis children. Ann Dermatol Venereol 2002 Jul; 129 Suppl.: 418
97. Reitamo S, for the European Tacrolimus Ointment Study group. 0.1% Tacrolimus ointment is significantly more efficacious than a steroid regimen in adults with moderate to severe topic dermatitis [abstract no. 129055 plus poster]. 1st EADV International Spring Symposium; 2003 Feb 27-Mar 1; St Julian's, Malta
98. Paller AS, Lebwohl M, Fleishcher AB, et al. Tacrolimus ointment is more effective than pimecrolimus cream with a similar safety profile in the treatment of atopic dermatitis: results from three randomized, comparative studies. J Am Acad Dermatol. In Press
99. Reitamo S, Harper J, Bos JD, et al. 0.03% Tacrolimus ointment applied once or twice daily is more efficacious than 1% hydrocortisone acetate in children with moderate to severe atopic dermatitis: results of a randomized double-blind controlled trial. Br J Dermatol 2004 Mar; 150 (3): 554-62
100. FK506 Ointment Study Group. Phase III comparative study of FK506 ointment. Group comparison study with betametasone valerate in atopic dermatitis: trunk and extremities. Nishi Ninon J Dermatol 1997; 59: 870-9
101. FK506 Ointment Study Group. Phase III comparative study of FK506 ointment. Group comparison study with alclometasone dipropionate in atopic dermatitis: face and neck. Acta Dermatologica (Kyoto) 1997; 92 (3): 277-88
102. Kang S, Lucky AW, Pariser D, et al. Long-term safety and efficacy of tacrolimus ointment for the treatment of atopic dermatitis in children. J Am Acad Dermatol 2001 Jan; 44 (1): S58-64
103. Kawashima M, FK506 Ointment Study Group. Long-term study of FK506 (tacrolimus) ointment in patients with atopic dermatitis. Analysis at the time of completion of 2-year observation. Rinsho Iyaku 2001; 17: 705-26
104. Hanifin JM, Leung DY, Paller A, et al. Tacrolimus ointment monotherapy is safe and effective for the long-term treatment (more than 3 years) of atopic dermatitis in pediatric patients [abstract no. 244]. J Allergy Clin Immunol 2003 Feb; III (2 Suppl.): S130
105. Paller A, Hanifin J, Eichenfield L, et al. Tacrolimus ointment monotherapy is a safe and effective treatment for atopic dermatitis long-term (more than 3 years) [abstract no. P24]. 61st Annual Meeting of the Am Academy of Dermatology; 2003 Mar 21-26; San Francisco
106. Rajka G, Langeland T. Grading of the severity of atopic dermatitis. Acta Derm Venereol Suppl (Stoch) 1989; 144: 13-4
107. Hanifin JM, Rajka G. Diagnostic features of atopic dermatitis. Acta Derm Venereol 1980; 92 Suppl.: 22-47
108. Hanifin JM, Thurston M, Omoto M, et al. The eczema area and severity index (EASI): assessment of reliability in atopic dermatitis. Exp Dermatol 2001; 10: 11-8
109. Ruzicka T. Efficacy and safety of tacrolimus ointment (Protopic) versus a mid-potent to potent corticosteroid in adults with moderate to severe atopic dermatitis. Ann Dermatol Venereol 2002 Jul; 129 Suppl.: 421
110. Shainhouse T, Eichenfield LF. Long-term safety of tacrolimus ointment in children treated for atopic dermatitis. Expert Opin Drug Saf 2003 Sep; 2 (5): 457-65
111. Koo JYM, Fleischer A, Pariser D, et al. Tacrolimus ointment 0.1% is safe and effective in the treatment for atopic dermatitis: final results of a large (over 7000 patients) open-label study [abstract no. P22]. 61st Annual Meeting of the American Academy of Dermatology; 2003 Mar 21-26; San Francisco
112. Remitz A, The European Tacrolimus Ointment Study Group. Flare prevention and clinical changes with long-term use of tacrolimus ointment in adults with moderate to severe atopic dermatitis. 11th Annual Congress of the European Academy of Dermatology and Venereology; 2002 Oct 2-6; Prague
113. Spergel JM, Prenner BM, Rico J, et al. Tacrolimus ointment monotherapy is a safe and effective treatment for mild atopic dermatitis [abstract no. 349]. J Allergy Clin Immunol 2003 Feb; 111 (2 Suppl.): 156
114. Schneider L, Berger W, Rico M, et al. Patients with severe atopic dermatitis benefit from tacrolimus ointment monotherapy [abstract no. 348]. J Allergy Clin Immunol 2003 Feb; 111 (2 Suppl.): 156
115. Kawakami T, Soma Y, Morita E, et al. Safe and effective treatment of refractory facial lesions in atopic dermatitis using topical tacrolimus following corticosteroid discontinuation. Dermatology 2001; 203 (1): 32-7
116. Nakagawa H, Eton T, Ishibashi Y, et al. Effects of tacrolimus (FK506) ointment for facial atopic dermatitis [abstract no. P-0860]. Eur J Allergy Clin Immunol 1995; 50 Suppl. 26: 683
117. Kang S, Paller A, Soter N, et al. Safe treatment of head/neck AD with tacrolimus ointment. J Dermatolog Treat 2003; 14 (2): 86-94
118. Krupnick Freeman A, Serle J, VanVeldhuisen P, et al. Tacrolimus ointment in the treatment of eyelid dermatitis. Therapeutics Clinician 2004 Apr; 73: 267-71
119. Rikkers SM, Holland GN, Drayton GE, et al. Topical tacrolimus treatment of atopic eyelid disease. Am J Ophthalmol 2003 Mar; 135 (3): 297-302
120. Nakata Y, Toyoda M. Practical use of tacrolimus with steroid-based conventional therapy [abstract and oral presentation]. Japn J Dermatol 2004; 114 (3): 130
121. Nakahara T, Koga T, Fukagawa S, et al. Intermittent topical corticosteroid/tacrolimus sequential therapy improves lichenification and chronic papules more efficiently than intermittent topical corticosteroid/ emollient sequential therapy in patients with atopic dermatitis. J Dermatol 2004 Jul; 31 (7): 524-8
122. Drake L, Prendergast M, Maher R, et al. The impact of tacrolimus ointment on health-related quality of life of adult and pediatric patients with atopic dermatitis. J Am Acad Dermatol 2001; 44: S65-72
123. Reitamo S. Quality of life improved in adults with moderate to severe atopic dermatitis with 0.1% tacrolimus ointment [abstract plus poster]. Congress of the European Academy of Dermatology and Venereology; 2004 29 Apr-1 May; Budapest
124. Lebwohl M, Freeman AK, Chapman MS, et al. Tacrolimus ointment is effective for facial and intertriginous psoriasis. J Am Acad Dermatol 2004 Nov; 51 (5): 723-30
125. Carroll CL, Clarke J, Camacho F, et al. Topical tacrolimus ointment combined with 6% salicylic acid gel for plaque psoriasis treatment. Arch Dermatol 2005 Jan; 141 (1): 43-6
126. Remitz A, Reitamo S, Erkko P, et al. Tacrolimus ointment improves psoriasis in a microplaque assay. Br J Dermatol 1999 Jul; 141: 103-7
127. Zonneveld IM, Rubins A, Jablonska S. Topical tacrolimus is not effective in chronic plaque psoriasis: a pilot study. Arch Dermatol 1998 Sep; 134: 1101-2
128. Yamamoto T, Nishioka K. Topical tacrolimus is effective for facial lesions of psoriasis [letter]. Acta Derm Venereol 2000 Nov 31; 80 (6): 451
129. Freeman AK, Linowski GJ, Brady C, et al. Tacrolimus ointment for the treatment of psoriasis on the face and intertriginous areas. J Am Acad Dermatol 2003 Apr; 48 (4): 564-8
130. Yamamoto T, Nishioka K. Topical tacrolimus: an effective therapy for facial psoriasis. Eur J Dermatol 2003 Sep-2003 31; 13 (5): 471-3
131. Ishiko A, Yokoyama T, Tanikawa A, et al. A case of generalised pustular psoriasis treated with topical tacrolimus. Arch Dermatol 2003; 139: 1219
132. Lepe V, Moncada B, Castanedo-Cazares JP, et al. A double-blind randomized trial of 0.1% tacrolimus vs 0.05% clobetasol for the treatment of childhood vitiligo. Arch Dermatol 2003 May; 139 (5): 581-5
133. Tanghetti EA. Tacrolimus ointment 0.1% produces repigmentation in patients with vitiligo: results of a prospective patient series. Cutis 2003 Feb; 71 (2): 158-62
134. Travis LB, Weinberg JM, Silverberg NB. Successful treatment of vitiligo with 0.1% tacrolimus ointment. Arch Dermatol 2003 May; 139 (5): 571-4
135. Smith DA, Tofte SJ, Hanifin JM. Repigmentation of vitiligo with topical tacrolimus [letter]. Dermatology 2002; 205 (3): 301-3
136. Grimes PE, Soriano T, Dytoc MT. Topical tacrolimus for repigmentation of vitiligo. J Am Acad Dermatol 2002 Nov; 47 (5): 789-91
137. Silverberg NB, Lin P, Travis L, et al. Tacrolimus ointment promotes repigmentation of vitiligo in children: a review of 57 cases. J Am Acad Dermatol 2004 Nov; 51 (5): 760-6
138. Kanwar AJ, Dogra S, Parsad D. Topical tacrolimus for treatment of childhood vitiligo in Asians. Clin Exp Dermatol 2004 Nov; 29 (6): 589-92
139. Castanedo-Cazares JP, Lepe V, Moncada B. Repigmentation of chronic vitiligo lesions by following tacrolimus plus ultraviolet-B-narrow-band [letter]. Photodermatol Photoimmunol Photomed 2003 Feb; 19 (1): 35-6
140. Plettenberg H, Assmann T, Ruzicka T. Childhood vitiligo and tacrolimus: immunomodulating treatment for an autoimmune disease. Arch Dermatol 2003 May; 139 (5): 651-4
141. Alomar A, Puig L, Gallardo CM, et al. Topical tacrolimus 0.1% ointment (Protopic®) reverses nickel contact dermatitis elicited by allergen challenge to a similar degree to mometasone furoate 0.1% with greater suppression of late erythema. Contact Dermatitis 2003 Oct; 49 (4): 185-8
142. Saripalli YV, Gadzia JE, Belsito DV. Tacrolimus ointment 0.1% in the treatment of nickel-induced allergic contact dermatitis. J Am Acad Dermatol 2003 Sep; 49 (3): 477-82
143. Fuchs M, Schliemann-Willers S, Heinemann C, et al. Tacrolimus enhances irritation in a 5-day human irritancy in vivo model. Contact Dermatitis 2002 May; 46 (5): 290-4
144. Braza TJ, DiCarlo JB, Soon SL, et al. Tacrolimus 0.1% ointment for seborrhoeic dermatitis: an open-label pilot study. Br J Dermatol 2003 Jun; 148 (6): 1242-4
145. Meshkinpour A, Sun J, Weinstein G. An open pilot study using tacrolimus ointment in the treatment of seborrheic dermatitis. J Am Acad Dermatol 2003 Jul; 49 (1): 145-7
146. Kaliakatsou F, Hodgson TA, Lewsey JD, et al. Management of recalcitrant ulcerative oral lichen planus with topical tacrolimus. J Am Acad Dermatol 2002 Jan; 46 (1): 35-41
147. Morrison L, Kratochvil 3rd FJ, Gorman A. An open trial of topical tacrolimus for erosive oral lichen planus. J Am Acad Dermatol 2002 Oct; 47 (4): 617-20
148. Vente C, Reich K, Rupprecht R, et al. Erosive mucosal lichen planus: response to topical treatment with tacrolimus. Br J Dermatol 1999 Feb; 140: 338-42
149. Hodgson TA, Sahni N, Kaliakatsou F, et al. Long-term efficacy and safety of topical tacrolimus in the management of ulcerative/erosive oral lichen planus. Eur J Dermatol 2003 Sep-2003 31; 13 (5): 466-70
150. Olivier V, Lacour JP, Mousnier A, et al. Treatment of chronic erosive oral lichen planus with low concentrations of topical tacrolimus: an open prospective study. Arch Dermatol 2002 Oct; 138: 1335-8
151. Rozycki TW, Rogers 3rd RS, Pittelkow MR, et al. Topical tacrolimus in the treatment of symptomatic oral lichen planus: a series of 13 patients. J Am Acad Dermatol 2002 Jan; 46 (1): 27-34
152. Lener EV, Brieva J, Schachter M, et al. Successful treatment of erosive lichen planus with topical tacrolimus. Arch Dermatol 2001 Apr; 137 (4): 419-22
153. Eisman S, Orteu CH. Recalcitrant erosive flexural lichen planus: successful treatment with a combination of thalidomide and 0.1% tacrolimus ointment. Clin Exp Dermatol 2004 May; 29 (3): 268-70
154. Kirtschig G, Van Der Meulen AJ, Ion Lipan JW, et al. Successful treatment of erosive vulvovaginal lichen planus with topical tacrolimus [letter]. Br J Dermatol 2002 Sep; 147 (3): 625-6
155. Byrd JA, Davis MD, Rogers 3rd RS. Recalcitrant symptomatic vulvar lichen planus: response to topical tacrolimus. Arch Dermatol 2004 Jun; 140 (6): 715-20
156. Goldman D. Tacrolimus ointment for the treatment of steroid-induced rosacea: a preliminary report. J Am Acad Dermatol 2001 Jun; 44: 995-8
157. Rao NG, Pariser RJ. Annular erythema responding to tacrolimus ointment. J Drugs Dermatol 2003 Aug; 2 (4): 421-4
158. Pabby A, An KP, Laws RA. Combination therapy of tetracycline and tacrolimus resulting in rapid resolution of steroid-induced periocular rosacea. Cutis 2003 Aug; 72 (2): 141-2
159. Goldman D, Gruchalla D, Shull T. Tacrolimus ointment for the treatment of steroid-induced rosacea [abstract no. P311]. 61st Annual Meeting of the American Academy of Dermatology; 2003 Mar 21-26; San Francisco
160. Bamford JT, Elliott BA, Haller IV. Tacrolimus effect on rosacea. J Am
161. Bernard LA, Cunningham BB, Al-Suwaidan S,et al. Arosacea-like granulomatous eruption in a patient using tacrolimus ointment for atopic dermatitis [letter]. Arch Dermatol 2003 Feb; 139: 229-31
162. Antille C, Saurai JH, Lubbe J. Induction of rosaceiform dermatitis during treatment of facial inflammatory dermatoses with tacrolimus ointment. Arch Dermatol 2004 Apr; 140 (4): 457-60
163. Soter N, Fleischer Jr AB, Webster GF, et al. Tacrolimus ointment for the treatment of atopic dermatitis in adult patients: Part II, safety. J Am Acad Dermatol 2001; 44: S39-46
164. Boguniewicz M, Leung DY, Webster GF, et al. Long-term safety of topically applied tacrolimus ointment in adult atopic dermatitis patients [abstract no. 471 plus oral presentation]. J Allergy Clin Immunol 2002 Jan; 109 (1 Suppl.): S160
165. Schneider L, Roberts R, Berger W, et al. Topically applied tacrolimus ointment in pediatric atopic dermatitis patients: results of a large open-label study [abstract no. 348]. J Allergy Clin Immunol 2002 Jan; 109 (1 Suppl.): 160
166. Koo J, Abramovits W, Fivenson D, et al. The experience of tacrolimus ointment in adult atopic dermatitis patients: results of two large open-label studies [abstract no. P105 plus poster]. 60th Annual Meeting of the American Academy of Dermatology; 2002 Feb 22-27; New Orleans, 42
167. Rico MJ, Koo J, Fleischer A, et al. Long-term tacrolimus ointment monotherapy effectively controls atopic dermatitis: results in 8000 patients [abstract no. plus poster]. 12th Annual Congress of the European Academy of Dermatology and Venereology; 2003 Oct 15-18; Barcelona
168. Milingou M, Antille C, Saurat JH, et al. Alcohol intolerance in adult patients with atopic dermatitis treated with 0.1% topical tacrolimus ointment [abstract no. SSS 10-8]. J Eur Acad Dermatol Venereol 2003; 17 Suppl. 3: 462
169. Reitamo S, Remitz A, Kyllonen H, et al. Topical noncorticosteroid immunomodulation in the treatment of atopic dermatitis. Am J Clin Dermatol 2002; 3 (6): 381-8
170. Sand C. Topical tacrolimus ointment may induce skin tags in treated patients [letter]. Acta Derm Venereol 2003; 83 (4): 317
171. Mickey JR, Robson A, Barker JN, et al. Does topical tacrolimus induce lentigines in children with atopic dermatitis? A report of three cases. Br J Dermatol 2005 Jan; 152 (1): 152-4
172. Kempers S, Boguniewicz M, Carter E, et al. A randomized investigator-blinded study comparing pimecrolimus cream 1% with tacrolimus ointment 0.03% in the treatment of pediatric patients with moderate atopic dermatitis. J Am Acad Dermatol 2004 Oct; 51 (4); 515-25
173. Kempers S, Jarrat M, Pariser D, et al. Pimecrolimus cream 1% demonstrates better local tolerability than tacrolimus ointment 0.03% in pediatric patients with atopic dermatitis. J Am Acad Dermatol 2004 Mar; 50 (3 Suppl.): 3
174. Fleischer AB Jr, Ling M, Eichenfield L, et al. Tacrolimus ointment for the treatment of atopic dermatitis is not associated with an increase in cutaneous infections. J Am Acad Dermatol 2002 Oct; 47 (4): 562-70
175. Wollenberg A, Wetzel S, Walter HC, et al. Viral infections in atopic dermatitis: pathogenic aspects and clinical management. J Allergy Clin Immunol 2003 Oct; 112 (4): 667-74
176. Lubbe J, Poumaras CC, Saurat J-H. Eczema herpeticum during treatment of atopic dermatitis with 0.1% tacrolimus ointment. Dermatology 2000; 201: 249-51
177. Wollenberg AZC, Wetzel S. Predisposing factors and clinical features of eczema herpeticum: a retrospective analysis of 100 cases. J Am Acad Dermatol 2003 Aug; 49 (2): 198-205
178. Lubbe J, Sanchez-Politta S, Tschanz C, et al. Adults with atopic dermatitis and herpes simplex and topical therapy with tacrolimus: what kind of prevention? Arch Dermatol 2003 May; 139 (5): 670-1
179. Ambo M. Relapsing Kaposi's varicelliform eruption and herpes simplex following facial tacrolimus treatment for atopic dermatitis. Acta Derm Venereol 2002 May 1; 82: 224-5
180. Miyaki-Kashima M, Fukugawa K, Tanaka M, et al. Kaposi varicelliform eruption associated with 0.1% tacrolimus ointment treatment of atopic blepharitis. Cornea 2004 Mar; 23 (2): 190-3
181. Wetzel S, Wollenberg A. Eczema molluscum in tacrolimus treated atopic dermatitis. Eur J Dermatol 2004; 14: 73-4
182. Wilson LM, Reid CM. Molluscum contagiosum in atopic dermatitis treated with 0.1% tacrolimus ointment. Australas J Dermatol 2004 Aug; 45 (3): 184-5
183. Lerbaek A, Agner T. Facial eruption of molluscum contagiosum during topical treatment of atopic dermatitis with tacrolimus. Br J Dermatol 2004; 150: 1210-1
184. Yamamoto T, Nishioka K. Deep dermatophytosis during topical tacrolimus therapy for psoriasis. Acta Derm Venereol 2003; 83 (4): 291-2
185. Ellis CN, Drake LA, Prendergast MM, et al. Cost-effectiveness analysis of tacrolimus ointment versus high-potency topical corticosteroids in adults with moderate to severe atopic dermatitis. J Am Acad Dermatol 2003 Apr; 48 (4): 553-63
186. National Institute for Clinical Excellence. Tacrolimus and pimecrolimus for atopic eczema. Technology Appraisal Guidance 82. London: National Institute for Clinical Excellence, 2004 Aug
187. Rustin M, The UK Tacrolimus Ointment Study group. Cost-effectiveness of tacrolimus ointment in the treatment of adults and children with moderate to severe atopic dermatitis in the UK [poster]. Congress of the European Academy of Dermatology and Venereology; 2004 29 Apr-1 May; Budapest
188. Abramovits W, Boguniewicz M, Prendergast MM, et al. Comparisons of efficacy and cost-effectiveness of topical immunomodulators in the management of atopic dermatitis. J Drug Assess 2003; 6: 13-26
189. Fujisawa GmbH. Protopic® 0.03% ointment. Summary of product characteristics. Munich: Fujisawa GmbH, 2002 Feb 28
190. Fujisawa GmbH. Protopic® 0.1% ointment. Munich: Fujisawa GmbH, 2002 Feb 28
191. Hoare C, Li Wan Po. A., Williams H. Systematic review of treatments for atopic eczema. Health Technol Assess 2000; 4 (37)
192. Jirapongsananuruk O, Leung DYM. Clinical applications of cytokines: new directions in the therapy of atopic diseases. Ann Allergy Asthma Immunol 1997 Jul; 79: 5-16
193. Atopic Dermatitis Guidelines/Outcomes Task Force. Guidelines of care for atopic dermatitis [online]. Available from URL: www.aadassociation.org [Accessed 2005 Feb 2]
194. Draelos ZD, Tofte S, Hanifin J, et al. Systemic exposure of pimecrolimus cream 1% and tacrolimus ointment 0.1% in adult patients with moderate to severe atopic dermatitis [abstract P13]. J Am Acad Dermatol 2004 Mar; 50 (3 Suppl.): P4
195. Wellington K, Noble S. Pimecrolimus: a review of its use in atopic dermatitis. Am J Clin Dermatol 2004; 5 (6): 479-95
196. Novartis Pharma GmbH. Elidel® (pimecrolimus) cream 1%. Prescribing information. Novartis Pharma GmbH, 2003
197. Patel RR, Vander Straten MR, Korman NJ. The safety and efficacy of tacrolimus therapy in patients younger than 2 years with atopic dermatitis. Arch Dermatol 2003 Sep; 139 (9): 1184-6
198. Housman TS, Norton AB, Feldman SR, et al. Tacrolimus ointment: utilization patterns in children under age 2 years. Dermatol Online J [online]. Available from URL: http://dermatology.cdlib.org/ [Accessed 2004 Aug 27]
199. Wahn U, Bos JD, Goodfield M, et al. Efficacy and safety of pimecrolimus cream in the long-term management of atopic dermatitis in children. Pediatrics 2002 Jul; 110 (1):
200. Pascual JC, Fleisher AB. Tacrolimus ointment (Protopic) for atopic dermatitis. Skin Therapy Lett 2004 Nov; 9 (9): 1-5